36.96
前日終値:
$37.23
開ける:
$37.32
24時間の取引高:
1.30M
Relative Volume:
0.73
時価総額:
$4.41B
収益:
$18.47M
当期純損益:
$-589.53M
株価収益率:
-7.0266
EPS:
-5.26
ネットキャッシュフロー:
$-399.80M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
+13.97%
6か月 パフォーマンス:
-19.34%
1年 パフォーマンス:
-34.48%
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CYTK
Cytokinetics Inc
|
36.96 | 4.61B | 18.47M | -589.53M | -399.80M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-24 | 開始されました | Barclays | Overweight |
2025-02-07 | 開始されました | Citigroup | Buy |
2025-01-22 | 開始されました | Stifel | Buy |
2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
2024-01-24 | ダウングレード | UBS | Buy → Neutral |
2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-11-09 | 開始されました | Goldman | Buy |
2023-11-07 | 開始されました | B. Riley Securities | Buy |
2023-08-15 | 開始されました | SVB Securities | Outperform |
2023-02-17 | 開始されました | BofA Securities | Neutral |
2022-12-23 | 繰り返されました | Needham | Buy |
2022-12-20 | 開始されました | Truist | Buy |
2022-10-11 | 開始されました | UBS | Buy |
2022-01-28 | 開始されました | Goldman | Buy |
2021-12-22 | 開始されました | Oppenheimer | Outperform |
2021-12-10 | 開始されました | JP Morgan | Overweight |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-03-12 | 開始されました | Wolfe Research | Outperform |
2021-02-18 | 開始されました | Barclays | Overweight |
2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-29 | 開始されました | Goldman | Neutral |
2020-07-10 | 開始されました | Raymond James | Strong Buy |
2020-05-05 | 開始されました | Mizuho | Buy |
2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
2017-07-31 | 開始されました | Morgan Stanley | Overweight |
2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
2016-07-28 | 繰り返されました | Needham | Buy |
2015-11-10 | 繰り返されました | FBR Capital | Outperform |
2015-11-09 | 繰り返されました | ROTH Capital | Buy |
2015-07-24 | 繰り返されました | MLV & Co | Buy |
2014-12-31 | 繰り返されました | ROTH Capital | Buy |
2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Is Cytokinetics Incorporated a good long term investmentTremendous financial leverage - jammulinksnews.com
Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
Cytokinetics Incorporated Stock Analysis and ForecastMarket-beating performance - jammulinksnews.com
What analysts say about Cytokinetics Incorporated stockHigh-octane financial growth - jammulinksnews.com
What drives Cytokinetics Incorporated stock priceUnmatched profit potential - jammulinksnews.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients - TipRanks
Cytokinetics CEO Makes a Significant Stock Move! - TipRanks
Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com Australia
Cytokinetics (CYTK) CEO Blum sells $190k in stock By Investing.com - Investing.com South Africa
Why Cytokinetics Incorporated stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
What makes Cytokinetics Incorporated stock price move sharplyDaily Swing Candidates - Newser
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire
CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - The Manila Times
Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 - Quiver Quantitative
Cytokinetics(CYTK) Soars 6.93% on Analyst Optimism - AInvest
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN
Cytokinetics (CYTK): Balancing Optimism and Caution in Aficamten's High-Stakes Journey - AInvest
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress - Yahoo.co
11 Best Most Active Stocks To Buy According to Analysts - Insider Monkey
Cytokinetics Aligns U.S., Europe, and Japan—Could Global Synchronization Fuel Explosive Growth? - Smartkarma
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM - ScienceDirect.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News - GuruFocus
Cytokinetics Awards 140,000 Shares Worth $2.9M in Employee Inducement GrantsSee Exercise Price - Stock Titan
Cytokinetics CEO Robert Blum sells $169,000 in stock By Investing.com - Investing.com Canada
Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook By Investing.com - Investing.com India
Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook - Investing.com
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program | CYTK Stock News - GuruFocus
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - The Manila Times
JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | CYTK Stock News - GuruFocus
Cytokinetics (CYTK) Target Price Cut by JPMorgan Analyst | CYTK Stock News - GuruFocus
JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | C - GuruFocus
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - mx.advfn.com
Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion By Investing.com - Investing.com Nigeria
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):